<DOC>
	<DOCNO>NCT02625779</DOCNO>
	<brief_summary>This research aim investigate efficacy safety creatine cytidine augmentation treat bipolar depression evaluate change relevant brain biochemical metabolism use proton phosphorous magnetic resonance spectroscopy .</brief_summary>
	<brief_title>Combined Cytidine Creatine-containing Drug Treatment Bipolar Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Aged 1965 year Bipolar disorder I II ( DSMIVTR ) current depressive episode Informed consent Use medication bipolar depression psychotropic drug Current Axis I mental disorder bipolar depression base structured clinical interview Current borderline antisocial personality disorder base structured clinical interview Major medical neurological illness ( epilepsy , multiple sclerosis , brain tumor , cerebrovascular disease , etc ) Hypersensitivity divalproate valpromide Diagnosis porphyria Current past liver disease Severe dysfunction liver pancreas Use mefloquine Alcohol substance abuse/dependence Intelligence quotient 80 Contraindications magnetic resonance imaging Pregnancy breastfeed Allergy intolerance study drug</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Bipolar depression</keyword>
	<keyword>Cytidine</keyword>
	<keyword>Creatine</keyword>
	<keyword>Magnetic resonance spectroscopy</keyword>
</DOC>